WHO WE ARE

TRC is a contract development manufacturer with a focus on inhalation and ophthalmic products. Our teams of experts manage programs from development through full scale commercialization, more efficiently and effectively than the competition.

FLEXIBILITY YOU CAN TRUST

We understand that drug development is complex. Our customers' needs can change in a moment and we know how to meet those challenges and keep projects on schedule.

OUR FACILITY
INDUSTRY LEADER IN THE
DEVELOPMENT AND
MANUFACTURING OF STERILE
UNIT DOSE PRODUCTS.

BFS CENTER OF EXCELLENCE
Over 20 years of experience producing for the respiratory, and ophthalmic product OTC markets.

270,000 SQ FT
FACILITY SPACE

In addition to the 120,000 sq ft of manufacturing space, we have a 150,000 sq ft packaging and distribution center.
1.7 BILLION UNIT
CAPACITY
Utilizing the latest technology in formulation, Blow Fill Seal, and high speed packaging, our team manages the production capacity of 1.7 Billion units annually.

FDA REGISTERED
503B OUTSOURCING
FACILITY
Ritedose 503b Outsourcing Facility, a division of The Ritedose Corporation, manufactures sterile products for hospitals and healthcare facilities throughout the United States.

MEDICATION THAT MATTERS

"At TRC we believe that we are not making products for faceless patients. We strive for unmatched quality and use the latest technology in all that we do because we have countless patients around the world that count on it."

JODY CHASTAIN, PRESIDENT & CEO

OUR PRODUCTS

PRODUCT TYPES

Solutions
Suspensions
Emulsions

PRODUCT MARKET

Inhalation
Ophthalmic
Otic
Oral

CONTAINER TYPES

Inhalation
Ear Drops
Eye Drops
Unique Patented Designs

OUR PROUD HISTORY

1995
TRC (formerly Holopack International) founded in Columbia SC
2000
TRC receives FDA approval to manufacture & distribute drug products
2003
TRC obtains first ANDA for Ipratroprium Bromide
2005
Installation of Rommelag 460 and automated packaging line Capacity of 500 Million units
2008
TRC obtains second ANDA for Albuterol Sulfate Capacity of 700 Million units
2009
Olympus Partners acquires Holopack International and forms The Ritedose Corporation
2012
TRC obtains third ANDA for IpratropriumAlbuterol
2013
EU compliant expansion Quality & Development Lab expansion
2016
TRC obtains fourth ANDA for Levalbuterol Capacity of 1.7 Billion units 10 BFS machines 4 fully automatic packaging lines 1 semi-automatic packing line
2017
TRC acquired by Humanwell Health Group
2018
Plant expansion of over 150,000 sq ft for packaging and distribution
2019
TRC registers with FDA as a 503B Outsourcing and Repackaging Facility